Cantor Fitzgerald Weighs in on ESPR FY2026 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Esperion Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will post earnings per share of $0.02 for the year. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

Other research analysts have also issued reports about the stock. The Goldman Sachs Group cut their target price on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Friday, April 25th. Finally, Needham & Company LLC decreased their target price on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $6.25.

Esperion Therapeutics Price Performance

NASDAQ:ESPR traded down $0.03 during trading hours on Wednesday, hitting $1.17. The stock had a trading volume of 2,145,207 shares, compared to its average volume of 5,293,574. The firm has a market capitalization of $231.89 million, a price-to-earnings ratio of -1.83 and a beta of 0.67. Esperion Therapeutics has a one year low of $0.69 and a one year high of $3.94. The company has a 50 day simple moving average of $0.95 and a two-hundred day simple moving average of $1.67.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The firm had revenue of $65.00 million during the quarter, compared to the consensus estimate of $54.97 million.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its position in Esperion Therapeutics by 18.6% during the 4th quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock valued at $5,399,000 after purchasing an additional 385,099 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Esperion Therapeutics by 602.8% during the fourth quarter. Victory Capital Management Inc. now owns 173,083 shares of the biopharmaceutical company's stock valued at $381,000 after buying an additional 148,456 shares during the last quarter. Bank of America Corp DE raised its holdings in Esperion Therapeutics by 45.1% in the 4th quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock worth $3,586,000 after purchasing an additional 506,428 shares during the period. Raymond James Financial Inc. bought a new position in shares of Esperion Therapeutics in the fourth quarter worth about $98,000. Finally, D. E. Shaw & Co. Inc. lifted its holdings in Esperion Therapeutics by 152.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 251,592 shares of the biopharmaceutical company's stock valued at $554,000 after purchasing an additional 152,019 shares in the last quarter. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.